



Clinical trial results:

T cell therapy for patients with advanced Renal Cell Carcinoma

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2016-001454-18 |
| Trial protocol | DK |
| Global end of trial date | 31 October 2021 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 04 October 2022 |
| First version publication date | 04 October 2022 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | UG1617 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02926053 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|-----------------------------------------------------------------------------------------------------------|
| Sponsor organisation name | Inge Marie Svane |
| Sponsor organisation address | Borgmester Ib Juuls Vej 25c, Herlev, Denmark, 2730 |
| Public contact | Mette Wassard Yde, National Center for Cancer Immune Therapy, 0045 38689339, mette.wassard.yde@regionh.dk |
| Scientific contact | Mette Wassard Yde, National Center for Cancer Immune Therapy, 0045 38689339, mette.wassard.yde@regionh.dk |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 31 October 2021 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 October 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 October 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate toxicity (according to CTCAE version 4.0) and feasibility.

Protection of trial subjects:

Standard-of-care

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|----------------|
| Actual start date of recruitment | 01 August 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Denmark: 5 |
| Worldwide total number of subjects | 5 |
| EEA total number of subjects | 5 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 5 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Danish patients with renal cell cancer was included in the period March 2017 - September 2019.

Pre-assignment

Screening details:

In total eight patients were found eligible. Five patient were included for treatment. Patients was not included due to clinical progression (1) or patient's wish/received other treatment (2).

Period 1

| | |
|------------------------------|-----------------------------|
| Period 1 title | Full trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|----------------------------------------|--------------------------------|
| Arm title | All patients |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | Tumor-infiltrating lymphocytes |
| Investigational medicinal product code | |
| Other name | TIL |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

TILs were infused day 0. Maximum number of cultured TILs were infused ranging from 46-96 x 10e9 cells

| | |
|----------------------------------------|------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | Cy |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Cyclophosphamide 60 mg/kg was administered once daily on day -7 and -6

| | |
|----------------------------------------|-----------------------|
| Investigational medicinal product name | Fludarabine phosphate |
| Investigational medicinal product code | |
| Other name | Fludara |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Fludarabine phosphate was administered once daily 25 mg/m² (max 50 mg) at days -5 to -1

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | Interleukin-2 |
| Investigational medicinal product code | |
| Other name | IL-2, aldesleukin |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous bolus use |

Dosage and administration details:

Interleukin-2 was administered as an intravenous bolus over 15 minutes at dose 600.000 IE/kg every 8 hours starting from day 0 for a maximum of 15 doses.

| Number of subjects in period 1 | All patients |
|---------------------------------------|--------------|
| Started | 5 |
| Completed | 5 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------|
| Reporting group title | Full trial |
|-----------------------|------------|

Reporting group description: -

| Reporting group values | Full trial | Total | |
|----------------------------------------------------|------------|-------|--|
| Number of subjects | 5 | 5 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 5 | 5 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 1 | 1 | |
| Male | 4 | 4 | |

Subject analysis sets

| | |
|----------------------------|------------------|
| Subject analysis set title | Treated patients |
|----------------------------|------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

All treated patients

| Reporting group values | Treated patients | | |
|----------------------------------------------------|------------------|--|--|
| Number of subjects | 5 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 5 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |

| | | | |
|--------------------|---|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 1 | | |
| Male | 4 | | |

End points

End points reporting groups

| | |
|-----------------------------------|------------------|
| Reporting group title | All patients |
| Reporting group description: - | |
| Subject analysis set title | Treated patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| All treated patients | |

Primary: Number of patients in which the treatment was tolerable

| | |
|-----------------------------------------------------------------|------------------------------------------------------------------------|
| End point title | Number of patients in which the treatment was tolerable ^[1] |
| End point description: | |
| Number of patients who received treatment according to protocol | |
| End point type | Primary |
| End point timeframe: | |
| Full trial | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: In this phase I study, the primary end point is tolerability and there is no appropriate statistical test

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | All patients | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 5 | | | |
| Units: patients | 5 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Infusion products with detectable in-vitro anti-tumor responses

| | |
|-------------------------------------------------------|-----------------------------------------------------------------|
| End point title | Infusion products with detectable in-vitro anti-tumor responses |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| Any time after the infusion product has been produced | |

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | All patients | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 5 | | | |
| Units: Infusion products | 4 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Objective response rate

| | |
|-------------------------------------------------------------------------------------|-------------------------|
| End point title | Objective response rate |
| End point description: | |
| Patients who achieved partial or complete response according to RECIST 1.1 criteria | |
| End point type | Secondary |
| End point timeframe: | |
| Full trial | |

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | All patients | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 5 | | | |
| Units: Patients | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Full trial

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 25 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | Treated patients |
|-----------------------|------------------|

Reporting group description: -

| Serious adverse events | Treated patients | | |
|---------------------------------------------------|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| number of deaths (all causes) | 5 | | |
| number of deaths resulting from adverse events | 0 | | |
| Blood and lymphatic system disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Treated patients | | |
|-------------------------------------------------------|------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| Nervous system disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | | |
| occurrences (all) | 2 | | |
| Hallucination | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |

| | | | |
|--------------------------------------|-----------------|--|--|
| Fatigue | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| occurrences (all) | 5 | | |
| Pain | | | |
| subjects affected / exposed | 4 / 5 (80.00%) | | |
| occurrences (all) | 4 | | |
| Performance status decreased | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| occurrences (all) | 5 | | |
| Weight increased | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 1 | | |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| occurrences (all) | 5 | | |
| Petechiae | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | | |
| occurrences (all) | 1 | | |
| Anaemia | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| occurrences (all) | 5 | | |
| Gastrointestinal disorders | | | |
| Constipation | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | | |
| occurrences (all) | 3 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 4 / 5 (80.00%) | | |
| occurrences (all) | 4 | | |
| Nausea | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | | |
| occurrences (all) | 5 | | |
| Stomatitis | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | | |
| occurrences (all) | 3 | | |
| Vomiting | | | |

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Melaena</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>2 / 5 (40.00%)</p> <p>2</p> <p>1 / 5 (20.00%)</p> <p>1</p> | | |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>5 / 5 (100.00%)</p> <p>5</p> | | |
| <p>Skin and subcutaneous tissue disorders</p> <p>Rash maculo-papular</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dry skin</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>2 / 5 (40.00%)</p> <p>2</p> <p>5 / 5 (100.00%)</p> <p>5</p> | | |
| <p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Myalgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 5 (20.00%)</p> <p>1</p> <p>3 / 5 (60.00%)</p> <p>3</p> | | |
| <p>Infections and infestations</p> <p>Infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 5 (80.00%)</p> <p>4</p> | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported